Rockville, MD, October 11, 2023 -- American Gene Technologies® (AGT™), a clinical-stage biotechnology company dedicated to improving human health through innovative gene and cell therapies, today announced that Jeff Galvin, Founder and Chief Executive Officer, will present at the ROTH MKM Healthcare Opportunities Conference held at The Yale Club in New York City, New York, on October 12, 2023. Management will also be available for one-on-one meetings.
Event: ROTH MKM Healthcare Opportunities Conference
Location: The Yale Club in New York City, NY
Formal Presentation: Thursday, October 12, 1:15pm ET
On August 9, 2023, AGT announced its entry into a merger agreement with 10X Capital Venture Acquisition Corp. III (10X III; (NYSE: VCXB)). Pursuant to the merger agreement, AGT intends to merge its HIV business with 10X III. Following the merger, the combined company will be renamed Addimmune™ and will focus on progressing AGT’s lead clinical asset, AGT103-T, and other potential therapeutic candidates aimed at improving the lives of people living with HIV. Prior to the merger, AGT will spin off its non-HIV business into a newly formed entity, which is expected to retain and operate under the AGT name.
About American Gene Technologies
American Gene Technologies (AGT) is a leading biotechnology company at the forefront of genetic science, dedicated to improving human health through innovative gene and cell therapies. AGT is committed to harnessing the power of genetic science to develop cutting-edge solutions that help to alleviate human suffering and improve the quality of life for individuals affected by devastating diseases. With a commitment to excellence in science and patient care, AGT is pioneering the future of medicine. For more, visit www.americangene.com.
Vice President of Marketing and Communications
American Gene Technologies